Key facts
- This page summarizes Jeffrey A. Meckler's Form 4 filing for Indaptus Therapeutics, Inc. (INDP).
- 6 reported transactions and 6 derivative rows are listed below.
- Accepted by SEC: 13 Feb 2026, 16:15.
Jeffrey A. Meckler - 11 Feb 2026 Form 4 Insider Report for Indaptus Therapeutics, Inc. (INDP)
- Reporting relationship
- Co-Chief Executive Officer, Director
- Issuer ticker
- INDP
- Reported as of
- 11 Feb 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 Feb 2026, 16:15:18 UTC
- Prior SEC filing
- 29 Dec 2025
- Next SEC filing
- 06 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jeffrey Meckler
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jeffrey A. Meckler filed Form 4 for Indaptus Therapeutics, Inc. (INDP) on 13 Feb 2026.
Change
- Previous filing in this sequence was filed on 29 Dec 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001506916
Primary reporting owner
Meckler Jeffrey A
- Relationship
- Co-Chief Executive Officer, Director
- Address
- C/O INDAPTUS THERAPEUTICS, INC, 3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK
- Signature
- /s/ Jeffrey Meckler
- Signature date
- 13 Feb 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
INDP
transaction
Derivative
Warrants (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -3,033
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 11 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,033
- Exercise price
- $47.60
- Footnotes
- F1
INDP
transaction
Derivative
Warrants (right to buy)
Award
- Transaction value
- Shares
- +3,033
- Change %
- Price
- Shares after
- 3,033
- Date
- 11 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,033
- Exercise price
- $1.75
- Footnotes
- F1
INDP
transaction
Derivative
Warrants (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -1,519
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 11 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,519
- Exercise price
- $29.40
- Footnotes
- F1
INDP
transaction
Derivative
Warrants (right to buy)
Award
- Transaction value
- Shares
- +1,519
- Change %
- Price
- Shares after
- 1,519
- Date
- 11 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,519
- Exercise price
- $1.75
- Footnotes
- F1
INDP
transaction
Derivative
Warrants (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -12,136
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 11 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,136
- Exercise price
- $8.30
- Footnotes
- F1
INDP
transaction
Derivative
Warrants (right to buy)
Award
- Transaction value
- Shares
- +12,136
- Change %
- Price
- Shares after
- 12,136
- Date
- 11 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,136
- Exercise price
- $1.75
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged.
SEC remarks
On June 26, 2025, the Company effected a 1-for-28 reverse stock split (the "Reverse Stock Split") of the Company's common stock. All amounts have been adjusted to give effect to the Reverse Stock Split.